CDG UPDATES
CDG UPDATES
发布者:CDG Capital 时间:2018年10月31日
Innovent Biologics, a China Suzhou-based biopharmaceutical company, completes its initial public offering in Hong Kong, with trading officially commencing today. The company is the largest Biotech company judging from its late stage product pipe lines and its comprehensive functional platform to debut in HK Exchange thus far.
Innovent prices its IPO at HK$13.98 per share, raising a total of HKD HK$3,155.3 million via an issuance of 236.35m shares. In addition to getting very strong cornerstone support from well-known investment funds when it launched the IPO book build, sources said they also heavily allocated the remaining shares to high quality well-known global investors.
The company's listing under such a challenging market affirms investors' confidence in its future development and the successful commercialization of its rich innovative drugs pipeline under development.
WeChat Official Account
Suite 4704, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong
Tel:852 3520 0635
Email: cdg@cdginv.com
©️ 2020 All Rights Reserved 晨岭资本有限公司 版权所有 粤ICP备2020113789号